A homozygous 32-bp deletion in the gene encoding CCR5(1) a major coreceptor
for HIV-1, leads to resistance to infection with HIV-1, and heterozygosity
for the deletion is associated with delayed disease progression in persons
infected with HIV-1. We investigated the effect of CCR5 heterozygosity on
disease progression as measured by both CD4(+) T-cell count decline and the
occurrence of clinical AIDS symptoms. Using a unified statistical model fo
r CD4 count progression and AIDS development, we examined whether the effec
t of CCR5 heterozygosity on clinical AIDS is direct or indirect through its
effect on CD4 counts. Based on data from the Multicenter AIDS Cohort Study
, we noted a protective effect of CCR5 heterozygosity on both CD4 cell coun
t progression and on AIDS occurrence. Furthermore, we found that this prote
ctive effect on the occurrence of AIDS was completely mediated through an e
ffect on the CD4 marker. Additional adjustment for the effect of an initial
viral load measurement indicate that CCR5 heterozygosity did not have pred
ictive value for either CD4 progression or the development of AIDS beyond i
ts association with early viral load.